Adropin in women with polycystic ovary syndrome
| Autor: | Agata Mierzwicka, Maja Jończyk, Alina Urbanovych, Justyna Kuliczkowska-Płaksej, Barbara Stachowska, Marek Bolanowski |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
medicine.medical_specialty Adolescent Endocrinology Diabetes and Metabolism medicine.medical_treatment Enzyme-Linked Immunosorbent Assay 030209 endocrinology & metabolism Body Mass Index Young Adult 03 medical and health sciences 0302 clinical medicine Endocrinology Insulin resistance Sex hormone-binding globulin Internal medicine medicine Humans Androstenedione biology Free androgen index business.industry Insulin Quantitative insulin sensitivity check index Blood Proteins Luteinizing Hormone medicine.disease Polycystic ovary Case-Control Studies biology.protein Intercellular Signaling Peptides and Proteins Female Follicle Stimulating Hormone Insulin Resistance Metabolic syndrome Peptides business Polycystic Ovary Syndrome |
| Zdroj: | Endokrynologia Polska. 70:151-156 |
| ISSN: | 2299-8306 0423-104X |
| DOI: | 10.5603/ep.a2018.0092 |
| Popis: | Introduction: Women with polycystic ovary syndrome (PCOS) frequently develop metabolic complications. Among the newly found factors responsible for metabolic disorders, adropin seems to be of a great significance. Material and methods: In total 134 women aged 17–45 years were enrolled. The PCOS group consisted of 73 women, diagnosed on the basis of Executive Committee of the European Society of Human Reproduction and Embryology — American Society for Reproductive Medicine (ESHRE-ASRM) criteria. All PCOS women presented phenotype A of PCOS. The control group consisted of 61 women with regular menstrual cycles, matched for nutritional status. All women underwent anamnesis, physical examination, anthropometric measurements, abdominal and transvaginal ultrasound, and dual-energy X-ray absorptiometry (DXA). Serum adropin levels were determined by ELISA. Biochemical [fasting glucose and insulin, oral glucose tolerance test, lipid and sex hormone-binding globulin (SHBG)] and hormonal (testosterone, androstenedione, luteinizing hormone, follicle-stimulating hormone and oestradiol) measurements were performed. Insulin resistance indices [(Homeostasis Model Assessment for Insulin Resistance (HOMA-IR), Quantitative Insulin Sensitivity Check Index (QUICKI), Matsuda] and free androgen index (FAI) were calculated according to the standard formula. Results: Serum adropin levels were lower in the PCOS group (0.475 ± 0.200 vs. 0.541 ± 0.220, p = 0.069), but the results were not statistically significant. Positive correlations among adropin and androstenedione levels were observed in the PCOS group (r = 0.27, p = 0.025). Conclusions: Women with PCOS have a different metabolic profile in comparison to women without this syndrome. We did not observe a statistically significant difference in adropin concentration between the PCOS and the healthy control group. Therefore, more studies regarding adropin in PCOS are needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|